Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol/norethisterone acetate/relugolix - Sumitomo Pharma America

Next Previous
Drug Profile

Estradiol/norethisterone acetate/relugolix - Sumitomo Pharma America

Alternative Names: E2/NETA; Estradiol/norethindrone acetate/relugolix - Sumitomo Pharma America; Low-dose hormonal add-back; MYFEMBREE; Relugolix combination tablet; Relugolix/estradiol hemihydrate/norethisterone acetate; RYEQO

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Myovant Sciences
  • Developer ASKA Pharmaceutical; Pfizer; Sumitomo Pharma America; Takeda
  • Class Analgesics; Antineoplastics; Contraceptives; Estrenes; Fluorobenzenes; Norpregnenes; Pyridazines; Pyrimidines; Small molecules; Thiophenes; Urea compounds
  • Mechanism of Action Estrogen receptor agonists; LHRH receptor antagonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain; Uterine leiomyoma
  • Phase III Pregnancy

Most Recent Events

  • 05 Jun 2025 Knight Therapeutics in-licenses Estradiol/norethindrone acetate/relugolix from Sumitomo Pharma America in Canada
  • 31 May 2024 ASKA Pharmaceutical in-licenses relugolix combination tablet from Takeda in Endometriosis in Japan
  • 31 Jan 2024 Launched for Pain (Combination therapy) in Canada (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top